clinical trial · NCT03627403
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera MyelofibrosisSelinexor
brief summary
This is a phase II, open label, prospective, single-arm study evaluating the efficacy and safety of selinexor in patients with PMF or secondary MF (PPV-MF or PET-MF) who are refractory or intolerant to ruxolitinib and/or any other experimental JAK1/2 inhibitors.
started
May 10, 2019
primary completion
Aug 16, 2023
completion
Mar 5, 2025
last updated
Oct 26, 2026
official title
A Phase II Study to Evaluate the Efficacy and Safety of Selinexor in Patients With Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol